Though debt funding for the Phadia and Dionex acquisitions will deteriorate its credit protection metrics, Thermo Fisher should have enough free cash flow to retire "a good amount of debt" over the next 12 to 18 months.
Full-text access for registered users only.
Existing users login here.
New to GenomeWeb? Register here quickly for free access.